ADD ANYTHING HERE OR JUST REMOVE IT…
Wrong menu selected
Acarix Acarix
  • Product

    Background

    • What is Coronary Artery Disease (CAD)?
    • Diagnosing CAD

    About the product

    • The CADScor® System
    • How does it work
  • Resources

    Testimonials

    • HCP stories
    • Patient stories

    References

    • Clinical Studies
    • Questionnaire
    • Downloads (US)
    • Downloads (EU)
    • Education

    Support

    • Training
    • FAQ
    • Reimbursement

    Physician Locator

    • Germany
  • Investors
    • Corporate Governance
    • General Meetings
    • Financial Reports and Calendar
    • The Acarix Share
    • Rights Issue/Warrant Program
    • Previous Rights Issue
    • Investor Presentations
  • Company

    Who we are

    • About Acarix
    • leadership
    • Join the team

    Get in touch

    • Contact us
    • Investigator Initiated Study
  • News
    • Press
    • Events
    • Social Media
Account
Search
Book a Demo
Acarix Acarix
Book a demo
Menu
author-avatar
News
August 28, 2024
28 Aug 2024

Acarix receives additional declaration of intent and fully secures the warrants of series TO 3 through guarantee agreements

Acarix AB ("Acarix" or the "Company"), a leader in rapid AI and acoustics-based cardiac diagnostics, announces that...
Continue reading
author-avatar acarix
Press
August 28, 2024
28 Aug 2024

Acarix receives additional declaration of intent and fully secures the warrants of series TO 3 through guarantee agreements

Acarix AB ("Acarix" or the "Company"), a leader in rapid AI and acoustics-based cardiac diagnostics, announces that...
Continue reading
author-avatar acarix
Press
August 26, 2024
26 Aug 2024

Acarix receives declarations of intent to exercise warrants of series TO 3

Acarix AB ("Acarix" or the "Company") has received declarations of intent to exercise Warrants of series TO 3 (the ...
Continue reading
author-avatar
News
August 26, 2024
26 Aug 2024

Acarix receives declarations of intent to exercise warrants of series TO 3

Acarix AB ("Acarix" or the "Company") has received declarations of intent to exercise Warrants of series TO 3 (the ...
Continue reading
author-avatar acarix
Press
August 6, 2024
03 Jul 2024

ACARIX GENOMFÖR EN RIKTAD EMISSION OM 21 MSEK

DETTA PRESSMEDDELANDE FÅR INTE OFFENTLIGGÖRAS, DISTRIBUERAS ELLER PUBLICERAS, VARKEN DIREKT ELLER INDIREKT, INOM ELLER TILL USA, AUSTRA...
Continue reading
author-avatar acarix
Press
August 6, 2024
03 Jul 2024

ACARIX CARRIES OUT A DIRECTED SHARE ISSUE OF SEK 21 MILLION

THIS PRESS RELEASE IS NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BE...
Continue reading
author-avatar acarix
Press
August 6, 2024
11 Apr 2024

KALLELSE TILL ÅRSSTÄMMA I ACARIX AB

Aktieägarna i Acarix AB, org.nr 559009-0667 ("Bolaget"), kallas härmed till årsstämma tisdagen den 14 maj 2024 kl. 10:00 i Ba...
Continue reading
author-avatar acarix
0 comments
Press
April 11, 2024
11 Apr 2024

NOTICE OF ANNUAL GENERAL MEETING IN ACARIX AB

The shareholders of Acarix AB, reg. no. 559009-0667 (the "Company"), are hereby invited to the annual general meeting on Tues...
Continue reading
author-avatar acarix
Press
August 6, 2024
11 Apr 2024

Acarix adopts new growth-focused business model and provides outlook update as part of our ongoing strategic review

Acarix, a leader in advanced acoustic- and algorithm-based cardiac diagnostics, announces the adoption of a new innovative usage-based ...
Continue reading
author-avatar acarix
Press
August 6, 2024
11 Apr 2024

Acarix antar ny tillväxtfokuserad affärsmodell och ger en uppdatering av strategiska och finansiella mål

Acarix, ledande aktör inom akustik- och algoritmbaserad hjärtdiagnostik, tillkännager idag införandet av en ny innovativ användarbasera...
Continue reading
author-avatar acarix
Press
August 6, 2024
01 Feb 2024

Acarix carries out a directed share issue of approximately SEK 33.7 million

THIS PRESS RELEASE IS NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BE...
Continue reading
author-avatar acarix
Press
August 6, 2024
01 Feb 2024

Acarix genomför en riktad emission om cirka 33,7 MSEK

DETTA PRESSMEDDELANDE ÄR EJ FÖR OFFENTLIGGÖRANDE, DISTRIBUTION ELLER PUBLICERING, VARKEN DIREKT ELLER INDIREKT, INOM ELLER TILL USA, AU...
Continue reading
  • 1
  • 2
  • 3
  • ›
  • »
Acarix AB
Jungmansgatan 12
211 19 Malmö
SE
[email protected]

Product

Background

  • What is Coronary Artery Disease (CAD)?
  • Diagnosing CAD

About the product

  • The CADScor® System
  • How does it work

Resources

Testimonials

  • HCP stories
  • Patient stories

Support

  • Training
  • FAQ

References

  • Clinical Studies
  • Downloads (US)
  • Downloads (EU)

Investors

  • Corporate Governance
  • General Meetings
  • Financial Reports and Calendar
  • The Acarix Share
  • Rights Issue
  • Investor Presentations

Company

Who we are

  • About Acarix
  • Management
  • Join the team

Get in touch

  • Contact us
  • LinkedIn
  • Twitter

News

  • Press
  • Events
  • Cookie policy
  • Privacy Policy: Clinical Studies
  • Privacy Policy
  • Cookie policy
  • Privacy Policy: Clinical Studies
  • Privacy Policy

Acarix, 2025. All rights reserved V5

  • Products
    • Background
    • What is Coronary Artery Disease
    • Diagnosing CAD
    • About the product
    • The Cadscor System
    • How Does it Work
  • Resources
    • Testimonial
    • HCP Stories
    • Patients Stories
    • References
    • Clinical Studies
    • Downloads (US)
    • Downloads (EU)
    • Support
    • Training
    • Faq
    • Reimbursement
    • Physician Locator
    • Germany
  • Investors
    • Corporate Governance
    • General Meetings
    • Financial Reports and Calendar
    • The Acarix Share
    • Right Issue
    • Previous Rights Issue
    • Investor Presentations
  • Company
    • Who we are
    • About Acarix
    • Leadership
    • Join The Team
    • Get in touch
    • Contact Us
    • Investigator Initiated Study
  • News
    • News
    • Press
    • Events
    • Socialmedia
Start typing to see products you are looking for.